Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-87890387
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
JNJ-87890387 is a fully human bispecific antibody designed to target both ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3) on tumor cells and the T-cell surface glycoprotein CD3. By binding ENPP3 with high affinity on tumor cells and engaging CD3 on T-cells, it acts as a T-cell redirector, stimulating immune-mediated cytotoxicity against ENPP3-expressing cancer cells. The drug is being developed primarily for the treatment of advanced solid tumors—including hepatocellular carcinoma, ovarian cancer (endometrioid), uterine cancer (endometrioid), colorectal adenocarcinoma, papillary renal cell carcinoma, and lung adenocarcinoma. Its mechanism involves both antibody-dependent cell cytotoxicity and direct stimulation of T lymphocytes to attack tumor cells[1][2][3][4][8].
- Other names
- anti-ENPP3/anti-CD3 bispecific antibody
02
Targets
ENPP3 (Ectonucleotide pyrophosphatase/phosphodiesterase 3)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on JNJ-87890387.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-87890387.